News

April 29, 2021

Getting Back to Business Safely: Canadian Mining and COVID-19 Testing 

Canadian mining has responded quickly and efficiently to COVID-19. 

A staple of Canada’s economy, the mining industry was forced to adapt much faster and more strategically than other key economic contributors. While a master of disaster preparedness and crisis management, nothing could ever quite prepare the industry for a global pandemic. Not only did the unknowns, challenges, and regulations force Canada’s mining sector to evolve almost immediately, the pandemic also impacted how the industry reacted to and collaborated with its partners, competitors, and counterparts across the globe. 

Internationally, Canada is one of the leading mining countries, as well as one of the largest producers of minerals and metals.1 The mining industry accounts for one in every 26 jobs in Canada and in 2019, it contributed to 5 per cent of Canada’s total nominal GDP.1 Beyond its economic contributions, mining is critical to the development of key resources – and particularly those that are essential to the health and safety of Canadians, especially during a pandemic; mined metals, such as copper, play a critical role in killing bacteria and prevent patients from acquiring infections.2 

When the pandemic hit, Canada’s mining industry could waste no time waiting in the wings.  

Rapid and innovative testing tools have provided Canadian mining with the support it needed to get back to business. 

Impact of COVID-19 

The mining industry needed an immediate solution that would address at-home concerns to resume both domestic and global operations: 

  • Revised health and safety protocols meant the implementation of social distancing, resulting in increased costs and limited production; 
  • Fly-in-fly-out operations and the unique nature of the industry made it difficult to prevent on-site transmission; 
  • Shutdown of operations forced cancelled and delayed shipments and broader supply chain issues; 
  • Fluctuations and volatility in international prices caused decreased demand for certain materials and products. 

Testing has become an additional layer of protection that has not only helped Canadian mining operations do their part in addressing such challenges but has also provided the critically important peace of mind to employers and various stakeholders and surrounding communities. 

Since the beginning of the pandemic, Precision Biomonitoring has been working closely with Canadian mining operations across the country to do just that. 

In April 2020, New Gold’s operation in Rainy River, Ontario was forced into a three-week long shutdown, immediately halting all operations and delaying major projects. Like other mining operations, the Rainy River site requires fly-in-fly-out for some of its full-time employees and contractors, increasing the likelihood of on-site transmission through frequent travel. Not only did this pose a threat to the health and safety of the mine’s employees, but also to its surrounding communities, particularly Indigenous groups, in the remote Northern Ontario region. Both New Gold and the communities were concerned and on high alert knowing that the region’s health services were not adequately equipped to handle an outbreak. 

Faced with the urgent need to resume critical operations, New Gold leveraged Precision Biomonitoring’s innovative Biomeme SARS-CoV-2 rapid point-of-need test to safely and steadily increase capacity, which is now at 100 per cent.  

Approved for use by Health Canada, the shelf-stable SARS-CoV-2, portable PCR test can process up to 9 samples in about 60 minutes (excluding sample prep),and performance is not affected by the currently identified variants. . Employee samples are collected, prepared and processed by trained clinical laboratory personnel. The test itself is pre-mixed and ready to use, making it ideal for remote locations, such as Rainy River, where rapid results are needed and access to clinical lab space is limited. Following COVID-19 protocols, Precision Biomonitoring was able to train the New Gold team on how to use the testing device both on-site and virtually. 

Voluntary testing has provided New Gold, its staff and neighbouring communities with peace of mind that health and safety and social responsibility remain top priorities amidst the constant changes of COVID-19. By creating virus-free zones, New Gold has been able to ensure that it has the rapid and around-the-clock insights and results, through 24-hour support and on-site testing, that it needs to make critical decisions each day that will keep its employees and communities safe. 

COVID-19 undoubtedly posed unprecedented challenges to the mining sector. However, with the support of on-site, rapid testing, companies have been able to resume critical operations while keeping employees, communities and families as safe as possible. 

The pandemic is not yet over, and it is likely to continue impacting Canada for years to come, including heightened concerns regarding safety. In the face of ongoing changes, and as the global pandemic continues to evolve, testing devices will provide the stability and peace of mind to mining, as well as other key industries, needed to resume business as usual and maintain Canada’s leadership in the natural resources space. 

  

To learn more about Precision Biomonitoring’s innovative COVID-19 testing tools, as well as its work with clients such as New Gold, please visit: https://precisionbiomonitoring.com/media/case-studies/  

About Precision Biomonitoring  

Founded in 2016, Precision Biomonitoring provides industry-leading expertise in molecular direction of organisms. Their very own TripleLock™ technology aims to deliver rapid, on-site environmental, food, animal and human diagnostic testing solutions. Customers are any organizations that need onsite surveillance and rapid identification of any organism in any environment. The Precision Biomonitoring team is at the forefront of technological innovations in the genomics industry. Our vision is a world where we can identify any organism on the spot, in an instant, anywhere on the planet. 

Sources

  1. Government of Canada. Minerals and the economy. Accessed April 2021. https://www.nrcan.gc.ca/our-natural-resources/minerals-mining/minerals-metals-facts/minerals-and-the-economy/20529
  2. Teck. The Role of Antimicrobial Copper. Accessed April 2021https://www.teck.com/responsibility/approach-to-responsibility/global-citizenship/copper-&-health/

Original news source: http://canadianminingmagazine.com/getting-back-to-business-safely-canadian-mining-and-covid-19-testing/


April 22, 2021

Precision Biomonitoring Receives Grant for Innovative Agrifood Testing Device to Safeguard Farm-to-Fork Continuum 

The CFIA awards grant funding through Innovative Solutions Canada for Project BISTRO for the detection of salmonella, listeria and other food borne pathogens in leafy greens and produce 

GUELPH, CANADA, and Ottawa, CANADA, April 22, 2021 – Precision Biomonitoring has received a grant from the Canadian Food Inspection Agency (CFIA) through the Innovative Solutions Canada (ISC) Program to develop a rapid, highly-sensitive, mobile and specific testing methodology aimed at the improved detection of food borne pathogenic bacteria.  

Project BISTRO aims to develop a rapid point-of-need solution to detect harmful pathogenic bacteria, including listeria and salmonella, particularly in leafy greens and produce, with greater sensitivity than current state-of-the-art testing technology. 

“As food borne illnesses rise, it will be important that Canada is equipped with the innovative tools and resources that will enable bacteria detection before products reach stores and consumers,” says Dr. Mario Thomas, CEO, Precision Biomonitoring. “We are looking forward to being able to potentially improve food borne illness detection that will ensure the health and safety of Canadians.” 

Project BISTRO is an ultra-portable, low-cost platform that uses on-site sample preparation tools with an integrated enrichment step to extract nucleic acids from various contaminated sample types. Using highly sensitive amplification coupled with digital lateral flow devices, the solution will be able to deliver reliable detection results in less than two hours. Project BISTRO is an adaptation of Precision Biomonitoring’s successful TripleLockTM platform, which was approved by Health Canada to support rapid testing needs in response to COVID-19. 

”If successful, a portable tool like this could  help reduce risk in food supply by detecting food borne pathogens throughout the farm-to-fork continuum,” says Tammy Switucha, Chief Food Safety Officer for Canada and Executive Director, Food Safety and Consumer Protection Directorate, CFIA. “The CFIA appreciates the work being done by Precision Biomonitoring to support innovation and evolve with rapidly changing technology that can help keep our food supply safe.”  

The device will provide food producers, farming and agriculture operations, distribution centres and large-scale grocers with peace of mind that they are providing their customers with safe food and produce. 

CFIA has awarded Precision Biomonitoring a Phase I grant through the ISC program to continue development of Project BISTRO. If successful, following Phase I and analysis of results, Precision Biomonitoring will apply for an additional ISC grant for Phase II, which would enable the partners to bring Project BISTRO from concept to commercialization. 

About Precision Biomonitoring  

Founded in 2016, Precision Biomonitoring provides industry-leading expertise in molecular direction of organisms. Their very own TripleLock™ technology aims to deliver rapid, on-site environmental, food, animal and human diagnostic testing solutions. Customers are any organizations that need onsite surveillance and rapid identification of any organism in any environment. The Precision Biomonitoring team is at the forefront of technological innovations in the genomics industry. Our vision is a world where we can identify any organism on the spot, in an instant, anywhere on the planet. 

About CFIA 

As a science-based regulator, the Canadian Food Inspection Agency (CFIA) has a broad mandate that encompasses food safety, animal health, plant health and international market access.  Mitigating risks to food safety is the CFIA’s highest priority, and the health and safety of Canadians is the driving force behind the design and development of CFIA programs. The CFIA, in collaboration and partnership with industry, consumers, and federal, provincial and municipal organizations, continues to work towards protecting Canadians from preventable health risks related to food and zoonotic diseases. 

  

Media Contact:   

Meredith Adams 
416-848-1609 
madams@national.com 


February 4, 2021

Precision Biomonitoring Receives Health Canada Approval for SARS-CoV-2 TRIPLELOCK™ 96-Well Laboratory Testing microplates

Canadian-Made TRIPLELOCK™ 96-Well Plates save time in the lab

GUELPH, ON, Feb. 4, 2021 /CNW/ – Precision Biomonitoring today announces it has received Health Canada approval for its TRIPLELOCK™ SARS-CoV-2 test in 96-Well Plate format. The recent approval makes the shelf-stable, ready-to-use, lyophilized testing plates available for immediate use in labs across Canada.

The TRIPLELOCK™ 96-Well Plates are highly reliable, with 100 per cent sensitivity and specificity with no cold-chain required, making them safe to ship and store at room temperature. The TRIPLELOCK™ 96-Well Plates are a cost-effective, scalable RT-PCR solution that detects the RNA of SARS-CoV-2 that causes COVID-19. The pre-aliquoted device includes 96 pre-loaded tests, saves time, supports larger testing volumes and is compatible with most lab instruments, making it an ideal solution for lab settings.

“We are thrilled with our third Health Canada approval, as we continue to tackle the difficulties of this pandemic, our testing solutions present a much-needed tool for labs across Canada to stay cost effective while supporting larger testing volumes,” says Dr. Mario Thomas, CEO, Precision Biomonitoring. “Our dedication to innovative testing is steadfast and we will continue to provide the tools needed to rapidly detect this virus and alleviate the pressures being placed on the healthcare system.” 

Precision Biomonitoring’s TRIPLELOCK™ SARS-CoV-2 test in 96-Well Plate format has already received CE Mark , helping to alleviate the pressures faced by healthcare systems, governments, front-line workers and businesses across Europe.

Precision Biomonitoring is a first mover in rapid, mobile diagnostic and detection kits in Canada. Its unique technology can be applied to any living organism, enabling customers to detect an organism or pathogen at the point-of-need and get a result immediately. Currently with three Health Canada and one European approval – making it the first and only Canadian-made solution to support Canada’s pandemic response.

About Precision Biomonitoring SARS-CoV-2 TRIPLELOCK™ 96-Well Plates

Precision Biomonitoring’s shelf-stable SARS-CoV-2 TRIPLELOCK™ 96-Well Plates are an innovative testing solution that detects the RNA of severe acute respiratory syndrome COVID-19. Because the test and the reagents are lyophilized in the wells, they are stable at room temperature. The portable, shelf-stable TRIPLELOCK™ 96-Well Plates can be transported without refrigeration and include 96 pre-aliquoted and pre-loaded lyophilized tests, making it ideal for supporting larger testing volumes. They save time in the lab because there is no mixing and aliquoting of many reagents. The two COVID-19 RNA targets are multiplexed together with an RNA positive control and are highly reliable with 100% sensitivity. Early identification and diagnosis of COVID-19 is crucial to ensure a rapid response, thus mitigating the possible additional negative consequences of the virus.

About Precision Biomonitoring

Founded in 2016 by a team of scientists from the University of Guelph’s Biodiversity Institute of Ontario, Canada, Precision Biomonitoring provides TRIPLELOCK™ onsite molecular surveillance platform solutions that give customers earlier detection of organisms for a more rapid response. Customers are any organizations that need onsite surveillance and rapid identification of any organism in any environment. The Precision Biomonitoring team is at the forefront of technological innovations in the genomics industry. Our vision is a world where we can identify any organism on the spot, in an instant, anywhere on the planet.

Original news source: Precision Biomonitoring Receives Health Canada Approval for SARS-CoV-2 TRIPLELOCK™ 96-Well Laboratory Testing microplates (newswire.ca)

Sales Inquiries: sales@precisionbiomonitoring.com


November 4, 2020

Health Canada Approves Precision Biomonitoring’s Canadian-Made Rapid SARS-CoV-2 Testing Device

The TRIPLELOCK™ Test Strips deliver COVID-19 results within 60 minutes
The First and Only Approved Canadian-Made Solution to Support Canada’s Response to the Pandemic

GUELPH, Ontario, November 4, 2020 – Precision Biomonitoring announced today it has received Health Canada approval for its ready-to-use thermostable SARS-CoV-2 TRIPLELOCK™ Test Strips for use across Canada. The TRIPLELOCK™ Test Strips are a rapid, point-of-need diagnostic RT-PCR test able to provide accurate results for 9 samples in just 60 minutes. This cost-effective, Canadian-manufactured test will help support the government and industry as Canada focuses on safely re-opening the economy amidst a second wave of the virus. Precision Biomonitoring announced in June that it received approval and funding from Next Generation Manufacturing Canada (NGen) to support manufacturing of its ready-to-use thermostable test.

“We are proud to be adding another Health Canada approval to the list of testing devices offered by Precision Biomonitoring. We have been working closely with various industries across Canada to help bring their workforce back safely, and are thrilled to be expanding that capability,” says Dr. Mario Thomas, CEO, Precision Biomonitoring. “This approval also means we can strengthen our ongoing support for federal and provincial governments, as well as Canadian industries.”

The SARS-CoV-2 TRIPLELOCK™ Test Strips are designed for accurate RT-PCR point-of-need diagnostics, are stable at room temperature, and  to be used by qualified laboratory personnel only. The lyophilized products combine the highest accuracy performance of RT-PCR with convenience of use and stability, which are crucial for remote parts of the country where adequate access to precise testing may be limited. 

“We are excited by today’s news as this approval is a huge step forward for Canadians as we continue our battle with COVID-19,” says Eric Hoskins, former Minister of Health and Long-Term Care of Ontario and Precision Biomonitoring Board Member. “The healthcare community has come together in incredible ways to help Canadians manage their way through this global pandemic. The thermostable TRIPLELOCK™ test that is now available will be crucial in workplaces across the country, schools, and rural and remote areas, where answers are needed fast.” 

Precision Biomonitoring also recently received CE Mark approval in Europe for its TRIPLELOCK™ SARS-CoV-2 test in 96-Well Plate format. Made available for immediate use in labs across Europe, the CE mark will help to address the rising demand for testing in various countries, including hotspot regions.

About Precision Biomonitoring Rapid SARS-CoV-2 TRIPLELOCK™ Test Strips 

Precision Biomonitoring’s easy-to-use Test Strips are a mobile solution for the healthcare community in Ontario and across Canada. The portable TRIPLELOCK™ Test Strips can be transported without refrigeration and when used by qualified lab personnel, are ideal when results are needed immediately in workplaces and more rural and remote regions. The SARS-CoV-2 TRIPLELOCK™ Test Strips detect the RNA of the severe acute respiratory syndrome, COVID-19. The COVID-19 RNA targets are multiplexed together with an RNA positive control. Early identification and diagnosis of COVID-19 is crucial to ensure a rapid response, thus mitigating the possible additional negative consequences of the virus. 

About Precision Biomonitoring  

Founded in 2016 by a team of scientists from the University of Guelph’s Biodiversity Institute of Ontario, Precision Biomonitoring provides TRIPLELOCK™ onsite eDNA surveillance platform solutions that give customers earlier detection of organisms for a more rapid response. Customers are any organizations that need onsite surveillance and rapid identification of any organism in any environment. The Precision Biomonitoring team is at the forefront of technological innovations in the genomics industry. Our vision is a world where we can identify any organism on the spot, in an instant, anywhere on the planet.  

Sales Inquiries:
info@pbidiagnostics.com

Media Contact:
Meredith Adams
416-459-7086
Madams@national.ca


October 29, 2020

CE Mark Approval Granted to Precision Biomonitoring’s SARS-CoV-2 TRIPLELOCK™ Test

Shelf-stable, ready-to-use testing plates compatible with COVID-19 testing labs

GUELPH, CANADA and BRUSSELS, BELGIUM, October 29, 2020 – Today, Precision Biomonitoring announced it has received CE Mark for its TRIPLELOCK™ SARS-CoV-2 test in 96-Well Plate format. This marking allows for the shelf-stable, ready-to-use, lyophilized testing plates to be made available for immediate use in labs across Europe, where daily infection rates have been increasing rapidly over the past few weeks. The TRIPLELOCK™ 96-Well Plates are highly reliable, with 100% sensitivity and specificity with no cold-chain required, making them safe to ship and run at room temperature.

The TRIPLELOCK™ 96-Well Plates are a cost-effective, scalable RT-PCR solution that detects the RNA of SARS-CoV-2 that causes COVID-19. The pre-aliquoted device includes 96 pre-loaded tests, saves time, supports larger testing volumes and is compatible with most lab instruments, making it an ideal solution for lab settings.

“With COVID-19 infection rates increasing in countries across Europe, governments, front-line healthcare workers and businesses need an arsenal of tools to help rapidly detect this virus,” says Dr. Mario Thomas, CEO, Precision Biomonitoring. “Our innovative testing solution will definitely help to alleviate pressures being placed on labs across Europe.”

The CE marking will help address the rising demand for testing in countries across Europe, including hotspot regions. Increased testing capacity will also help to alleviate pressures on the European healthcare systems that are experiencing an increase in hospitalizations as a result of a growing number of positive cases amongst the senior demographics.

“Precision Biomonitoring’s innovative test will be a supportive solution as we address the immediate testing needs across Europe,” says Greg Henderson, International Business Development Director, Precision Biomonitoring. “It will also help to alleviate additional concerns such as limited laboratory capacity as well, as countries across Europe continue to face increased testing demands and positive cases.”

Precision Biomonitoring continues to work with other partners and stakeholders around the world to leverage and distribute its additional testing solutions, including the VOILÀ!TM Rapid Digital Saliva Tests.

About Precision Biomonitoring SARS-CoV-2 TRIPLELOCK™ 96-Well Plates

Precision Biomonitoring’s shelf-stable SARS-CoV-2 TRIPLELOCK™ 96-Well Plates are an innovative testing solution that detects the RNA of severe acute respiratory syndrome COVID-19. Because the test and the reagents are lyophilized in the wells, they are stable at room temperature. The portable, shelf-stable TRIPLELOCK™ 96-Well Plates can be transported without refrigeration and include 96 pre-aliquoted and pre-loaded lyophilized tests, making it ideal for supporting larger testing volumes. They save time in the lab because there is no mixing and aliquoting of many reagents. The two COVID-19 RNA targets are multiplexed together with an RNA positive control and are highly reliable with 100% sensitivity. Early identification and diagnosis of COVID-19 is crucial to ensure a rapid response, thus mitigating the possible additional negative consequences of the virus.

About Precision Biomonitoring 

Founded in 2016 by a team of scientists from the University of Guelph’s Biodiversity Institute of Ontario, Canada, Precision Biomonitoring provides TRIPLELOCK™ onsite molecular surveillance platform solutions that give customers earlier detection of organisms for a more rapid response. Customers are any organizations that need onsite surveillance and rapid identification of any organism in any environment. The Precision Biomonitoring team is at the forefront of technological innovations in the genomics industry. Our vision is a world where we can identify any organism on the spot, in an instant, anywhere on the planet. 

SOURCE Precision Biomonitoring

Media Contact: Ahbab Choudhury, +44 7990 668 585, achoudhury@axon-com.com


July 07, 2020

Health Canada Authorizes Precision Biomonitoring to Import and Sell Biomeme’s SARS-CoV-2 Real-Time RT-PCR Test in Response to COVID-19

Ultra-portable testing solution approved for use across Canada

GUELPH, ON and PHILADELPHIA, July 7, 2020 /CNW/ – Biomeme and Precision Biomonitoring, industry leaders in rapid DNA field detection, announce that Health Canada has approved Biomeme’s SARS-CoV-2 Real-Time RT-PCR Test and rapid mobile detection platform for immediate deployment across Canada by Precision Biomonitoring. Approval was based on lab validation data generated through stringent testing of viral samples in performance areas including sensitivity and specificity. The approval is aligned with the Government of Canada’s ongoing commitment to collaborate with innovative companies dedicating their efforts to combating the pandemic.

“This approval is the result of the dedication and commitment of our teams at Precision Biomonitoring and Biomeme, as well as ongoing collaboration with our validation partners,” says Dr. Mario Thomas, CEO of Precision Biomonitoring. “This rapid test can now be distributed everywhere across Canada, especially in remote areas and workplaces where creating virus-free zones is vital. We can now bring the lab to the sample.”

More About the Biomeme Device & Software

Weighing only 1.2 kg, battery-operated and able to deliver results for up to nine samples in about 60 minutes, the mobile device and its easy-to-use software are ideal for all locations where screening is needed such as assessment centers, long-term care and nursing homes, retirement communities, ships, airports, borders and more distant regions. Precision Biomonitoring has also partnered with Guelph-based environmental consulting firm, Shared Value Solutions, to bring the approved rapid mobile testing platform to Indigenous communities in northern Ontario in response to COVID-19.

A free and intuitive smartphone mobile app pairs wirelessly with the device to easily run, monitor, and analyze the results of each test. Tests can be run online or offline, results can be interpreted in real-time, and all data can be securely synced to the cloud. Both the device and smartphone can be transported in a laptop-sized bag making it ideal for spot tests, especially when results are now needed in emergency rooms and more rural and remote regions.

More About the Test

The SARS-CoV-2 Real-Time RT-PCR Test requires no special lab equipment or cold chain and is intended for the qualitative detection of RNA from SARS-CoV-2 in nasopharyngeal and oropharyngeal (throat) swab samples. The assay’s two RNA targets are multiplexed together with Biomeme’s RNA extraction and RT-PCR process control in a single triple reaction. While being able to perform these tests in remote areas and workplaces is critical, the SARS-COV-2 test is also being manufactured in form factors suitable for high throughput labs. Here is a summary of each shelf-stable, pre-mixed form factor approved for use by health care providers across Canada:

  • 3-Well Go-StripsTM: Optimized for performance in the field. Each Go-StripTM has 3 reaction wells and each well contains a 20 µL lyophilized triplex reaction. With this form factor, there is no aliquoting or mixing of components in the field. You just add your sample to the strips and begin your test.
  • 96-Well Go-PlatesTM: Optimized for high throughput lab use in standard commercial thermocyclers (Bio-Rad CFX96, ABI QuantStudio5). Just like above, each Go-PlateTM is shelf-stable, pre-mixed, and pre-aliquoted with the same lyophilized triplex reaction.
  • Bulk Vials: Optimized more for lab use in any thermocycler. Each vial is shelf-stable, pre-mixed and lyophilized, but they are not pre-aliquoted, so you are free to use your own plastics.

“Having a reliable rapid test is critical for controlling the spread of COVID-19, especially in certain communities or rural settings where testing may take longer. It will allow these communities to get results faster and will enable healthcare professionals to take the necessary steps to expedite their response to COVID-19 cases,” said Dr. Rob Kozak, clinical microbiologist at Sunnybrook Health Sciences Centre.

The approval from Health Canada, combined with these capabilities and various form factors, allows Precision Biomonitoring to contribute to initiatives and programs recently implemented by the Government of Canada, as well as close to home in Ontario, where the government continues to focus on increasing testing capacity and creating safe workplaces.

To learn more about the different COVID-19 testing kits available, please visit pbidiagnostic.com

Third Party Clinical Evaluations

Northwell Health is New York State’s largest healthcare employer, with more than 68,000 employees and home to 23 hospitals and more than 700 outpatient facilities, as well as urgent care centers, kidney dialysis centers, acute inpatient rehabilitation, sub-acute rehabilitation and skilled-nursing facilities, a home care network, a hospice network, and other services. Northwell completed a clinical evaluation of the Biomeme SARS-CoV-2 Real-Time RT-PCR Test with clinical nasopharyngeal and oropharyngeal samples with a range of Ct values. This evaluation utilized 65 samples tested with 4 comparator platforms: GenMark ePlex, Hologic Panther Fusion, Wadsworth/CDC and Roche Cobas 8800. It found a 98% correlation (64/65).

About Precision Biomonitoring 

Founded in 2016 by a team of scientists from the University of Guelph’s Biodiversity Institute of Ontario, Precision Biomonitoring provides TripleLock™ onsite eDNA surveillance platform solutions that give customers earlier detection of organisms for a more rapid response. Customers are any organizations that need onsite surveillance and rapid identification of any organism in any environment. The Precision Biomonitoring team is at the forefront of technological innovations in the genomics industry. Our vision is a world where we can identify any organism on the spot, in an instant, anywhere on the planet. 

About Biomeme

Biomeme entered into molecular detection over 7 years ago when it created the first iPhone add-on capable of performing real-time PCR. Since its inception, Biomeme has used advanced biology and chemistry, along with world-class hardware and software engineering, to create elegant solutions to complex problems. Headquartered in Philadelphia, USA, Biomeme offers a full suite of end-to-end mobile molecular solutions. Biomeme’s 1-minute sample prep, shelf-stable reagents, hand-held thermocycler, cloud portal, and web API perform to the gold standard used by the world’s most advanced central labs but require no lab equipment or special experience to use.

SOURCE Precision Biomonitoring

For further information: Media Contact: Meredith Adams, 416-459-7086, Madams@national.ca


July 7, 2020

Precision Biomonitoring Announces Appointment of Dr. Eric Hoskins to Board of Directors

Dr. Hoskins Brings Expertise to Precision Biomonitoring’s Innovative Efforts in Health

GUELPH, ON and MISSISSAUGA, ON, July 7, 2020 /CNW/ – Precision Biomonitoring, an industry leader in offering point-of-need molecular detection tools for rapid results on the spot, is pleased to announce that Dr. Eric Hoskins, former Minister of Health of Ontario, has joined Precision Biomonitoring’s Board of Directors.

“We are looking forward to working closely with Dr. Hoskins,” says Dr. Mark Goldberg, Chair, Precision Biomonitoring board of directors. “His established leadership and experience in Canadian healthcare will be an asset and complement to the existing expertise we have at Precision Biomonitoring, especially as we continue our focus on the health of Canadians through our efforts in response to COVID-19.”

Dr. Hoskins has over thirty years’ experience as a physician and public health specialist. Most recently, Dr. Hoskins was Chair of the Federal Advisory Council on the Implementation of National Pharmacare.

Dr. Hoskins’ political experience will also bring valuable insights to Precision Biomonitoring as it continues to work closely with partners in government, health and technology innovation. Throughout his nearly ten years in provincial politics, Dr. Hoskins held critical roles, including as Ontario’s Minister of Health and Long-Term Care (2014-2018) where he was responsible for one of the largest healthcare systems in North America.

“Precision Biomonitoring is passionate about creating innovative Canadian solutions that serve and protect the health of Canadian and global citizens,” says Dr. Hoskins. “Their vision is closely aligned with my own and I am excited to join their Board as they make important advancements in the healthcare space.”

Additional members of Precision Biomonitoring’s Board of Directors include Dr. Mario Thomas, Co-founder and CEO, Precision Biomonitoring; Dr. Mark Goldberg, Co-founder, Plantform Inc.; John Ferraro, Chairman, JS Ferraro & Co.; John Pearson, President, QDZ Enterprises Ltd.

About Precision Biomonitoring 

Founded in 2016 by a team of scientists from the University of Guelph’s Biodiversity Institute of Ontario, Precision Biomonitoring provides TripleLock™ onsite eDNA surveillance platform solutions that give customers earlier detection of organisms for a more rapid response. Customers are any organizations that need onsite surveillance and rapid identification of any organism in any environment. The Precision Biomonitoring team is at the forefront of technological innovations in the genomics industry. Our vision is a world where we can identify any organism on the spot, in an instant, anywhere on the planet. 

SOURCE Precision Biomonitoring

For further information: Media Contact: Meredith Adams, 416-459-7086, Madams@national.ca


April 10, 2020

Collaboration to Provide Rapid SARS-CoV-2 Go-Strips to Communities in Northern Ontario

GUELPH, ON and MISSISSAUGA, ON, April 9, 2020 /CNW/ – Precision Biomonitoring, an industry leader in offering point-of-need molecular detection tools for rapid results on the spot, has announced its partnership with Guelph-based environmental consulting firm, Shared Value Solutions, to bring its point-of-need SARS-CoV-2 Go-Strips and rapid mobile detection device to Indigenous communities in northern Ontario, in response to COVID-19.

“We are all in this together,” says Dr. Mario Thomas, CEO, Precision Biomonitoring. “For Canada to be successful in both flattening the curve and eventually combatting the virus, we need to ensure that all Canadians are receiving access to necessary tools, especially communities who are most vulnerable. Our rapid point-of-need solution is designed to do just that.”

At present, the delivery of COVID-19 test results can take up to seven days in northern road-connected communities and can take even longer in more remote communities. With the ability to administer nine tests per hour at the point-of-need and deliver results in about 60 minutes, the 1.2 kg battery-operated, mobile COVID-19 test solution will help to increase testing speed and capacity.

Precision Biomonitoring’s SARS-CoV-2 Go-Strips are currently awaiting expedited approval from Health Canada. Shared Value Solutions is hopeful that it will be able to provide this testing technology to northern Indigenous communities in Ontario and across Canada in the near future, immediately following Health Canada approval.

The collaborative efforts of Precision Biomonitoring and Shared Value Solutions will help to address the growing number of cases in First Nations and Inuit communities, as recently confirmed by Indigenous Services Canada (ISC), while also supporting the federal government’s commitment to the well-being of these vulnerable populations, as made evident by the new distinctions-based Indigenous Community Support Fund to address immediate needs related to COVID-19.

“From creating a hand sanitizer supply chain for the north to offering free support to First Nations departments operating with limited capacity, we are doing everything we possibly can to support our clients’ greatest needs during this crisis. This new rapid testing option fills a crucial part of that need,” says Scott Mackay, CEO, Shared Value Solutions. “To be able to provide support alongside the dedicated team at Precision Biomonitoring, who already shares an interest in issues important to Indigenous communities, including environmental protection, makes us truly confident that this collaboration will provide the innovative care and testing desperately needed in these communities.”

About Precision Biomonitoring 
Founded in 2016 by a team of scientists from the University of Guelph’s Biodiversity Institute of Ontario, Precision Biomonitoring provides TripleLock™ onsite eDNA surveillance platform solutions that give customers earlier detection of organisms for a more rapid response. Customers are any organizations that need onsite surveillance and rapid identification of any organism in any environment. The Precision Biomonitoring team is at the forefront of technological innovations in the genomics industry. Our vision is a world where we can identify any organism on the spot, in an instant, anywhere on the planet. 

About Shared Value Solutions
Shared Value Solutions (SVS) is an environmental and community development consulting firm based in Ontario with employees also based in British Columbia, Alberta and New Brunswick. Our team works for and with Indigenous nations across Canada, providing technical guidance, regulatory advice, environmental peer reviews, negotiation and business strategy, and various supporting studies in relation to resource and infrastructure projects in our clients’ territories. Our company is made up of an interdisciplinary group of environmental scientists, planners, anthropologists and social researchers, and community engagement practitioners with a wide range of experience working for Indigenous communities, tribal councils and governments across the country. At the core of SVS’s work is the integration of environmental, social, cultural, economic values, advocacy for community health and well-being, and the protection of the environment and Indigenous rights.

SOURCE Precision Biomonitoring

For further information: Media Contact: Meredith Adams, 416-459-7086, Madams@national.ca


March 31, 2020

Precision Biomonitoring Receives Letter of Intent from the Government of Canada for its Testing Capabilities in Response to COVID-19

Point-of-need COVID-19 test awaiting approval by Health Canada 

GUELPH, Ontario and MISSISSAUGA, Ontario, March 31, 2020 – Precision Biomonitoring, an industry leader in developing environmental DNA (eDNA) tools to detect organisms at the point-of-need in 60 minutes, announces that it has been selected by the Government of Canada through a Letter of Intent with Public Services and Procurement Canada (PSPC) and Innovation, Science and Economic Development Canada (ISED) for its point-of-need SARS-CoV-2 Go-Strips test and battery-operated instrument in response to COVID-19. Precision Biomonitoring is one of the first ten companies to receive a Letter of Intent in the COVID-19 procurement space.

SARS-CoV-2 Go-Strips detect the RNA of severe acute respiratory syndrome, COVID-19. The COVID-19 RNA targets are multiplexed together with Biomeme’s RNA positive control, which is an RNA extraction and RT-PCR control, allowing results to be obtained onsite in 60 minutes. Early identification and diagnosis of COVID-19 is crucial to ensure a rapid response, thus mitigating the possible additional negative consequences of the virus. Weighing only 1.2 kg and battery-operated, Precision Biomonitoring’s mobile solution is ideal for all point-of-need locations where screening is needed for vulnerable populations such as assessment centers, long-term care homes, ships, airports, borders and more distant regions and remote areas. The test is currently awaiting Health Canada approval.

“We are immensely proud to have been selected as an early partner by our Federal Government,” says Dr. Mario Thomas, CEO, Precision Biomonitoring. “Precision Biomonitoring’s innovative point-of-need testing device addresses the call made by the Government of Canada’s Plan to Mobilize Industry to fight COVID-19. By pivoting and building from our experience in the sensitive area of food and water safety we are now looking forward to working with the Canadian health care community during this unprecedented time.”

With the ability to administer nine tests per hour at the point-of-need in 60 minutes, the SARS-CoV-2 Go-Strips will help contribute to the call from all levels of government to increase testing capacity for COVID-19. 

About Precision Biomonitoring SARS-CoV-2 Go-Strips

Precision Biomonitoring’s easy-to-use Go-Strips are a mobile solution for health care providers in Ontario and across Canada. The device can be transported in a laptop-sized bag, ideal for on the spot tests, especially when results are needed now in emergency rooms and more rural and remote regions.

About Precision Biomonitoring 

Founded in 2016 by a team of scientists from the University of Guelph’s Biodiversity Institute of Ontario, Precision Biomonitoring provides TripleLock™ onsite eDNA surveillance platform solutions that give customers earlier detection of organisms for a more rapid response. Customers are any organizations that need onsite surveillance and rapid identification of any organism in any environment. The Precision Biomonitoring team is at the forefront of technological innovations in the genomics industry. Our vision is a world where we can identify any organism on the spot, in an instant, anywhere on the planet. 

Media Contact:  

Meredith Adams 

416-459-7086 

Madams@national.ca


March 20, 2020

Precision Biomonitoring Announces its Health Canada Submission for Point-of-Care SARS CoV-2 Go-Strips

Precision Biomonitoring Responds to Health Canada’s Call for COVID-19 Research and Development with Innovative Point-of-Care Testing Solution

GUELPH, Ontario and MISSISSAUGA, Ontario, March 20, 2020 – Precision Biomonitoring, an industry leader in developing environmental DNA (eDNA) tools to detect organisms, announces the submission of its point-of-care SARS-CoV-2 Go-Strips and rapid mobile detection device to Health Canada for approval and use in Canada in response to the COVID-19 virus. The submission was based on lab validation data generated  through testing viral samples and its on-going collaboration with major research institutions in Ontario and Manitoba, including with teams that recently identified and isolated the RNA of the new novel coronavirus.

Our recent collaboration with healthcare and research institutions across the country positions us well to work with the Government of Canada and healthcare decision makers to provide innovative, point-of-care testing for COVID-19 in 60 minutes,” says Dr. Mario Thomas, CEO, Precision Biomonitoring. “We are looking forward to playing our part in combatting this virus.”

A proud Canadian company, Precision Biomonitoring, recognizes the importance of working with public health officials to ensure the safety of all Canadians. “Our technologies are inspired by our ongoing pursuit for innovation, and in the face of a rapidly evolving situation such as COVID-19, that relentless commitment is all the more critical,” says Thomas. “To know that our company is working towards supporting health care professionals in enabling the diagnosis and care taking place across Canada continues to fuel our efforts. We look forward to a timely response from Health Canada.”

Precision Biomonitoring has a demonstrated track record of being agile and adjusting to the scientific and medical needs of the Canadian landscape. Its ongoing work and strong existing relationships with the Government of Canada, as well as the Canadian Food Inspection Agency in the food safety and animal health space, has provided Precision Biomonitoring with the knowledge and experience necessary to be a trusted, collaborative partner to Health Canada.

About Precision Biomonitoring

Founded in 2016 by a team of scientists from the University of Guelph’s Biodiversity Institute of Ontario, Precision Biomonitoring provides TripleLock™ onsite eDNA surveillance platform solutions that give customers earlier detection of organisms for a more rapid response. Customers are any organizations that need onsite surveillance and rapid identification of any organism in any environment. The Precision Biomonitoring team is at the forefront of technological innovations in the genomics industry. Our vision is a world where we can identify any organism on the spot, in an instant, anywhere on the planet.

Media Contact: 

Meredith Adams

416-459-7086

madams@national.ca 


July 3, 2019
Precision Biomonitoring and AgriSeq Solutions Announce Strategic Partnership in Genomics


June 18, 2019
Precision Biomonitoring and Birks Natural Heritage Consultants Announce Strategic Partnership Advancing Adoption of Environmental DNA Methods http://bit.ly/2ZxV5cN 


May 14, 2019
Precision Biomonitoring Inc. and EcoMetrix Inc. have joined forces to advance the state of basic and applied science as it relates to Environmental DNA (eDNA) tools, approaches and methodologies. http://bit.ly/2WIHb6w


May 7, 2019
Precision Biomontoring Awarded ‘Build in Canada Innovation Program’ Contract. https://bit.ly/2GkKdaY

https://www.uoguelph.ca/ib/PISCeS


October 11, 2018
Precision Biomonitoring sponsors the first National eDNA National Workshop hosted by University of Guelph on October 11-12,2018

info@precisionbiomonitoring.com
1-888-444-7702


Office Address:
Orchard Park – Suite #226 
5420 Highway 6 North
Guelph ON  Canada
N1H 6J2

Lab Address:
361 Southgate Drive
Guelph ON Canada
N1G 3M5